Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Seres Therapeutics's price to sales ratio was 7.8× on Nov 11, 2026, against 449.2× a year earlier. Over the last 5 years it ranged from 0.9× to 449.2×, with a median of 50.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.8× | −363.7 |
| 2025 | Dec 31, 2025 | 371.6× | +39.2 |
| 2024 | Oct 31, 2024 | 332.4× | +331.0 |
| 2023 | Dec 29, 2023 | 1.4× | −50.7 |
| 2022 | Dec 30, 2022 | 52.1× | +47.2 |
| 2021 | Dec 31, 2021 | 4.9× | −91.1 |
| 2020 | Dec 31, 2020 | 96.0× | +89.6 |
| 2019 | Dec 31, 2019 | 6.4× | −2.5 |
| 2018 | Dec 31, 2018 | 8.9× | −3.9 |
| 2017 | Dec 29, 2017 | 12.8× | −8.5 |
| 2016 | Dec 30, 2016 | 21.3× | – |
See a number that looks wrong?